prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
apvma veterinary use permit 12551- autogenous staphylococcus hyicus vaccine/ pigs/ greasy pig disease.
apvma permit - vaccine - greasy pig - vaccine
apvma veterinary use permit 12552- custom autogenous haemophilus parasuis vaccine/ pigs/ glassers disease
apvma permit - vaccine - glassers - vaccine
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
protech c2i canine coronavirus & leptospira copenhageni killed vaccine
boehringer ingelheim animal health australia pty. ltd. - leptospira icterohaemorrhagiae antigen; canine coronavirus vaccine - antigen - misc. vaccines or anti sera - leptospira icterohaemorrhagiae antigen vaccine-antigen active 1.0 rp; canine coronavirus vaccine - antigen vaccine-viral active 1.62 rp - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus
vaxsafe ibd vaccine (living)
bioproperties pty. ltd. - infectious bursal disease virus strain v877 (live) - misc. vaccines or anti sera - infectious bursal disease virus strain v877 (live) vaccine-viral active 0.0 undefined - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - infectious bursal disease | bursal disease
respisure mh/hps vaccine (inactivated)
zoetis - vaccine - mycoplasma hyopneum.+vaccine - glassers - parenteral liquid/solution/suspension - vaccine - pigs | boar | gilt | piglet | sow | swine - glassers disease | growth suppression | haemophilus parasuis serovar 13 | haemophilus parasuis serovar 4 | haemophilus parasuis serovar 5 | lung lesions | mycoplasma hyopneumoniae | polyserositis | respiratory disease | reduction of lung lesions | respiratory disease | swine enzootic pneumonia
websters bursavac k infectious bursal disease vaccine (oil adjuvanted inactivated v877 strain virus)
zoetis australia pty ltd - infectious bursal disease virus (ibd) strain v877 - misc. vaccines or anti sera - infectious bursal disease virus (ibd) strain v877 vaccine-viral active 0.0 p - immunotherapy - fowl - infectious bursal disease | vaccine | bursal disease | equine rotavirus
mmr ii vaccine
merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (at end of expiry); mumps vaccine 12500 tcid50 (at end of expiry); rubella vaccine 1000 tcid50 (at end of expiry) - suspension for injection - active: measles vaccine 1000 tcid50 (at end of expiry) mumps vaccine 12500 tcid50 (at end of expiry) rubella vaccine 1000 tcid50 (at end of expiry) excipient: dibasic potassium phosphate dibasic sodium phosphate monohydrate eagle minimum essential medium gelatin medium 199 monobasic potassium phosphate monobasic sodium phosphate monohydrate monosodium glutamate neomycin phenolsulfonphthalein sodium bicarbonate sorbitol sucrose water for injection - m-m-r ii is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.